# US 2021/0284606 A1 · Tetralin and indane derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0284606 A1
- Document ID: US20210284606A1
- Status: Published application
- Kind: A1
- Application number: 17/328,165
- Filed: 2021-05-24
- Published: 2021-09-16
- Earliest claimed: 2004-12-21
- Assignees: Roche Palo Alto LLC
- Applicants: Roche Palo Alto LLC
- Inventors: Robert Greenhouse; Ralph New Harris, III; Saul Jaime-Figueroa; James M. Kress; David Bruce Repke; Russell Stephen Stabler
- Web page: https://patentgrep.com/patent/US20210284606A1

## CPC

- C07C 317/32: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 317/44: having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 207/325: with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 207/36: Oxygen or sulfur atoms
- C07D 209/30: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D 231/18: One oxygen or sulfur atom
- C07D 233/20: with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/34: Ethylene-urea
- C07D 233/44: Nitrogen atoms not forming part of a nitro radical
- C07D 233/48: with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
- C07D 233/54: having two double bonds between ring members or between ring members and non-ring members
- C07D 233/58: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 233/84: Sulfur atoms
- C07D 233/88: Nitrogen atoms, e.g. allantoin
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 239/14: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 277/82: Nitrogen atoms
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R1 R5, R6 and R7 are as defined herein.

## Claims

### Claim 1

A method for treating a central nervous system disease mediated by the 5-HT6 receptor wherein the disease is selected from the group consisting of state selected from psychoses, schizophrenia, manic depressions, neurological disorders, attention deficit disorder, Parkinson's disease, amyotrophic lateral sclerosis, food uptake disorders, and Huntington's disease, wherein the method comprises administering to said subject in need there a therapeutically effective amount of a compound of formula (I)
wherein:
m is 0 or 1;
s is 0 to 2;
R7 is halo, alkyl, alkoxy, haloalkyl, hydroxy, cyano or methanesulfonyl;
R1 is halo;
one of R5 and R6 is hydrogen or alkyl, and other of R5 and R6 is hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or amidinyl; or,
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein m is 0, s is 1, R7 is 3-fluoro, R5 is hydrogen and R6 is acetyl, aminocarbonyl or methylsulfonyl or a pharmaceutically acceptable salt.

### Claim 3 (depends on 1)

The method of claim 1 wherein the compound is (R)-[6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea or a pharmaceutically acceptable salt.

### Claim 4 (depends on 3)

The method of claim 3, wherein the central nervous system disease state is depression.

### Claim 5 (depends on 3)

The method of claim 3, wherein the central nervous system disease state is a memory disorder.

### Claim 6 (depends on 3)

The method of claim 3, wherein the central nervous system disease state is Parkinson's disease.
